| Literature DB >> 34111888 |
Jianying Liu1,2, Yang Liu3, Hongjie Xia3, Jing Zou3, Scott C Weaver1,2,4,5,6, Kena A Swanson7, Hui Cai7, Mark Cutler7, David Cooper7, Alexander Muik8, Kathrin U Jansen7, Ugur Sahin9, Xuping Xie10, Philip R Dormitzer11, Pei-Yong Shi12,13,14,15,16.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve around the world, generating new variants that are of concern based on their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutics1-5. Here we report that 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the newly emerged B.1.617.1, B.1.617.2, B.1.618 (all first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titers against the variant viruses, particularly the B.1.617.1 variant, appear lower than the titer against USA-WA1/2020 virus, but all sera tested neutralize the variant viruses at titers of at least 40. The susceptibility of these newly emerged variants to BNT162b2 vaccine-elicited neutralization supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic across geographies.Entities:
Year: 2021 PMID： 34111888 DOI： 10.1038/s41586-021-03693-y
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962